Impact of the Spatial Resolution of Several Contrast-enhanced 3D T1-WI Sequences When Diagnosing Giant Cell Arteritis (GCA)

Launched by FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD · May 9, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the best ways to use MRI (a type of imaging) to diagnose Giant Cell Arteritis (GCA), a serious condition that causes inflammation in large blood vessels, particularly in people over 50. The goal is to see if using lower-resolution MRI images can still provide accurate diagnoses, making this important test more widely available, especially in places that may not have access to high-resolution imaging equipment.

To participate in the trial, individuals must be over 18 years old and be referred for an MRI due to suspected GCA, showing certain symptoms like recent headaches or visual problems. Participants will undergo specific MRI scans to help in diagnosis. It's important to note that people with certain health conditions, recent cancers, or those who are pregnant may not qualify for this study. This research aims to improve how doctors diagnose GCA early, which is crucial for preventing serious complications.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient over 18 years of age
• • Referred for imaging for an injected MRI for suspected GCA
• * Suspicion of GCA based on the presence of three major criteria or two major and one minor criteria defined as follows:
• • Major criteria: Age \> 50 years; Headache of recent onset; Claudication of the jaw, tongue or swallowing disorders; Visual problems (blindness, diplopia, blurred vision - including visual accidents occurring during the first week of treatment); Sedimentation rate at 1st hour \> 50 and/or CRP \> 8mg/l
• • Minor criteria: Hypersensitivity or induration of the scalp or presence of nodules remote from the temporal artery; Temporal artery abnormalities on palpation; Facial pain or feeling of facial edema; General signs (fever \>38°C, weight loss \>10%, anorexia, malaise, asthenia).
• • Cconsent to participate in the study
• • Affiliated or beneficiary of a social security plan
• Exclusion Criteria:
• • Newly diagnosed malignant disease (diagnosed less than one year prior to inclusion)
• • Active infectious disease
• • Autoimmune disease (especially but not limited to: Wegener's disease, Takayasu vasculitis, ANCA vasculitis, rheumatoid arthritis, lupus erythematosus, periarteritis nodosa).
• • Systemic corticosteroid therapy for more than 10 days at high dose (\>0.5mg/kg/d of prednisone)
• • Contraindication to MRI
• • Patient benefiting from a legal protection measure
• • Pregnant or breastfeeding woman